Zobrazeno 1 - 10
of 162
pro vyhledávání: '"Selezneva Nd"'
Autor:
E. V. Ponomareva, Selezneva Nd, Gavrilova Si, N A Didkovsky, Ya. B. Fedorova, I. V. Kolykhalov, N. A. Khailov, S A Krynskiy, I K Malashenkova, D P Ogurtsov
Publikováno v:
Medicinskaâ Immunologiâ, Vol 23, Iss 4, Pp 805-812 (2021)
Alzheimer’s disease (AD) is currently the most common cause of dementia. A significant role in the pathogenesis of AD belongs to the activation of the mechanisms of neuroinflammation. There is a hypothesis that chronic infections may play a role in
Autor:
E. V. Ponomareva, D. O. Koroev, A. V. Kamynina, Olga M. Volpina, I. V. Kolykhalov, Ya. B. Fedorova, Selezneva Nd, Gavrilova Si
Publikováno v:
Neuroscience and Behavioral Physiology. 49:523-534
Objectives. Therapeutic monitoring and evaluation of the efficacy of neurotrophic therapy in patients with amnestic-type mild cognitive decline syndrome (aMCI) were performed in a model using courses of cerebrolysin. Materials and methods. A total of
Autor:
Selezneva Nd, Gavrilova Si, Ya. B. Fedorova, E. V. Ponomareva, U A Gutner, A. V. Alesenko, I. V. Kolykhalov, M. A. Shupik, A. O. Lebedeva
Publikováno v:
Neuroscience and Behavioral Physiology. 49:147-152
Objectives. To determine the efficacy and safety of treatment with Cereton (alfoscerate) in patients with mild cognitive impairment syndrome (MCI) and its effects during and after treatment on phosphatidyl-choline, sphingomyelin, and ceramide (a sphi
Autor:
E. D. Kosmacheva, Alekhin Mn, Evdokimova Ma, M. A. Chichkova, N. R. Khasanov, V. A. Brazhnik, D. A. Zateyshchikov, A. S. Galyavich, A. Yu. Kapustina, N. A. Koziolova, Boeva Oi, V. O. Konstantinov, Tereshchenko Sn, Selezneva Nd, Chumakova Os, M G Glezer, V. I. Safaryan, L. O. Minushkina
Publikováno v:
Kardiologiia. 61(8)
Aim To evaluate the prognostic significance of the left ventricular global function index (LV GFI) in patients with acute coronary syndrome (ACS) using echocardiography (EchoCG).Material and methods The LV GFI is an index that integrates LV cavity vo
Autor:
G. V. Kazanova, Ya. B. Fedorova, N. A. Khailov, I K Malashenkova, N. A. Didkovskii, E. V. Ponomareva, Selezneva Nd, Gavrilova Si, D P Ogurtsov, B. B. Velichkovskii, I. V. Kolykhalov, S. A. Krynskii
Publikováno v:
Neuroscience and Behavioral Physiology. 47:694-698
Objective. To assess the levels of cytokines (IFN-α, IL-2, IL-4, IL-6, IL-8, IL-10, IL-12, IL-15, TNF-α) and IL-1 receptor antagonist (IL-1RA), as well as the levels of vascular endothelial growth factor (VEGF) and its antagonist – soluble recept
Autor:
Boris B. Velichkovsky, A A Khlebnikova, Roshchina If, Dmitry V. Tatarinov, Selezneva Nd, Gavrilova Si
Publikováno v:
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 121:71
To study the effectiveness of interfering visual stimuli inhibition using the flanker task in a group of healthy young and healthy old participants, and in a group of participants with mild cognitive impairment (MCI).Reaction times and accuracy, as w
Publikováno v:
Neuroscience and Behavioral Physiology. 46:365-370
Study aim. The therapeutic efficacy and tolerance of agomelatine (Valdoxan) in mild and moderate depressive states were studied in out-patient conditions in a contingent of elderly patients. Materials and methods. Patients aged 60–75 years with mil
Publikováno v:
Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 120:31
To assess the delayed effect of course therapy with cerebrolysin on the cognitive functioning of the first degree relatives of patients with Alzheimer's disease (AD), including, depending on the ApoE4 genotype.A cohort of 72 blood relatives of patien
Autor:
N A Didkovsky, Ya. B. Fedorova, S A Krynskiy, Selezneva Nd, Gavrilova Si, D P Ogurtsov, I. V. Kolyhalov, N A Hailov, I K Malashenkova, E. V. Ponomareva
Publikováno v:
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 118(5)
To study clinical effects of cerebrolysin and its impact on systemic inflammation markers and immunity in mild cognitive impairment (MCI).Twenty patients with MCI were treated with cerebrolysin administered intravenously during 4 weeks. Serum levels
Publikováno v:
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. 118(5)
To study the efficacy and safety of cereton (choline alfoscerate) in the treatment of elderly patients with amnestic type of mild cognitive impairment (aMCI), which often represents a pre-dementia (symptomatic) stage of Alzheimer's disease (AD).Fifty